Abstract
Background Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the disorder as potentially pathogenic variants can reside in genes that are not yet known to be involved in kidney disease. To help identify these genes, we have developed KidneyNetwork, that utilizes tissue-specific expression to predict kidney-specific gene functions.
Methods KidneyNetwork is a co-expression network built upon a combination of 878 kidney RNA-sequencing samples and a multi-tissue dataset of 31,499 samples. It uses expression patterns to predict which genes have a kidney-related function and which (disease) phenotypes might result from variants in these genes. We applied KidneyNetwork to prioritize rare variants in exome sequencing data from 13 kidney disease patients without a genetic diagnosis.
Results KidneyNetwork can accurately predict kidney-specific gene functions and (kidney disease) phenotypes for disease-associated genes. Applying it to exome sequencing data of kidney disease patients allowed us to identify a promising candidate gene for kidney and liver cysts: ALG6.
Conclusion We present KidneyNetwork, a kidney-specific co-expression network that accurately predicts which genes have kidney-specific functions and can result in kidney disease. We show the added value of KidneyNetwork by applying it to kidney disease patients without a molecular diagnosis and consequently, we propose ALG6 as candidate gene in one of these patients. KidneyNetwork can be applied to clinically unsolved kidney disease cases, but it can also be used by researchers to gain insight into individual genes in order to better understand kidney physiology and pathophysiology.
Significance statement Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the patient’s disorder. Potentially pathogenic variants can reside in genes not yet known to be involved in kidney disease, making it difficult to interpret the relevance of these variants. This reveals a clear need for methods to predict the phenotypic consequences of genetic variation in an unbiased manner. Here we describe KidneyNetwork, a tool that utilizes tissue-specific expression to predict kidney-specific gene functions. Applying KidneyNetwork to a group of undiagnosed cases identified ALG6 as a candidate gene in cystic kidney and liver disease. In summary, KidneyNetwork can aid the interpretation of genetic variants and can therefore be of value in translational nephrogenetics and help improve the diagnostic yield in kidney disease patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Dutch Kidney Foundation grant 18OKG19 to AMvE. The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council (MRC) have also funded research infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
SAMPLE1-13: all exome sequencing data was generated as part of the diagnostic process. Patients signed informed consent for the use of their genetic data for both diagnostic and research purposes. We minimalised the amount of data included for patients SAMPLE1-5;7-13 and the treating physician asked additional consent from SAMPLE6 for inclusion of medical data and imaging. LE1 + 97.1: written informed consent was obtained from study participants of two research cohorts (Institutional Review Board, Leipzig University/Institute of Human Genetics Bioscientia - IRB00001750). For LE1 reference #289/20-ek and for 97.1 reference #402/16-ek applies. GEL1-8: genome sequencing data + clinical information were collected within the Genomics England 100,000 Genomes Project, approved by HRA Committee East of England - Cambridge South Research Ethics Committee - REC reference 14/EE/1112. All data included in this manuscript was approved via the Airlock Process of Genomics England (https://research-help.genomicsengland.co.uk/display/GERE/5.+The+Airlock).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
To make the gene-co-regulation-based HPO predictions publicly available a website was constructed: https://kidney.genenetwork.nl/. Informed consent did not cover uploading exome sequencing data from patients.
